Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing
With several recent FDA approvals and a strong drug pipeline, the gene therapy market is coming of age and providing new hope for patients. As demand for these new therapies increases, a robust and scalable manufacturing process is critical. In this webinar, we will present an end user case study which illustrates the challenges and solutions to scale both the upstream and downstream process steps required to manufacture adenoviruses.
Participants will learn how to:
• Accelerate time to market for adenovirus manufacturing
• Design the process for scalability
• Reduce downstream processing time from 3 - 4 days to 1 day
Speakers
Clive Glover, PhD
Rachel Legmann, PhD
Senior Manager, Process Development Services
Pall Biotech
Case Study: An End-to-End Solution for Large Scale Adenovirus Manufacturing
Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing
Biotech | Pall Corporation webinar series
Integrity Assurance for Single-Use Systems An End-User’s Perspective
What should you consider when building an integrity control strategy for your single-use systems (SUS)? How do you overcome application challenges?
Join leading industry experts Charlotte Masy of GSK and Patrick Evrard from Pall Corporation to gain insights and answers in this webinar from BioPharma Asia on integrity Assurance for Single-Use Systems, an End-User’s Perspective. They will present several case studies to show how integrity concerns can be practically addressed for cGMP manufacturing applications and the results observed a few years on.
Attendees will learn about:
- The latest regulatory requirements for integrity assurance of SUS
- The different technologies available to control integrity of SUS
- Key parameters that affect integrity measurements
Register now for this webinar from industry experts on October 6.